CA2001673A1 - Pharmaceutical composition containing piroxicam - Google Patents
Pharmaceutical composition containing piroxicamInfo
- Publication number
- CA2001673A1 CA2001673A1 CA2001673A CA2001673A CA2001673A1 CA 2001673 A1 CA2001673 A1 CA 2001673A1 CA 2001673 A CA2001673 A CA 2001673A CA 2001673 A CA2001673 A CA 2001673A CA 2001673 A1 CA2001673 A1 CA 2001673A1
- Authority
- CA
- Canada
- Prior art keywords
- mass
- parts
- particle size
- pharmaceutical composition
- composition containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising N-(2-piridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide as active ingredient and a process for preparing the same.
The composition is composed of 1 part by weight of N-(2-piridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide as active ingredient which at least in 90% by mass has a particle size of at most 30 /um, preferably 10 /um, if desired, 0.1 to 5.0 parts by mass, preferably 1 part by mass, of mannitol optionally of the same particle size, if desired, 0.005 to 0.15 parts by mass, preferably 0.06 to 0.1 parts by mass of silica optionally of the same particle size, 5 to 25 parts by mass, preferably 8 to 18 parts by mass, of spray-dried lactose which at least in 80% by mass has a particle size of 80 to 200 /um, if desired, 0.5 to 6.0 parts by mass, preferably 1.5 to 4.0 parts by mass, of a disintegrant, preferably corn starch, if desired, 0.005 to 0.05 parts by mass, preferably 0.01 to 0.02 parts by mass, of a surface active agent, preferably sodium lauryl sulfate, and if desired, 0.05 to 0.5 parts by mass, preferably 0.1 to 0.2 parts by mass of a lubricant, preferably magnesium stearate.
The composition is composed of 1 part by weight of N-(2-piridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide as active ingredient which at least in 90% by mass has a particle size of at most 30 /um, preferably 10 /um, if desired, 0.1 to 5.0 parts by mass, preferably 1 part by mass, of mannitol optionally of the same particle size, if desired, 0.005 to 0.15 parts by mass, preferably 0.06 to 0.1 parts by mass of silica optionally of the same particle size, 5 to 25 parts by mass, preferably 8 to 18 parts by mass, of spray-dried lactose which at least in 80% by mass has a particle size of 80 to 200 /um, if desired, 0.5 to 6.0 parts by mass, preferably 1.5 to 4.0 parts by mass, of a disintegrant, preferably corn starch, if desired, 0.005 to 0.05 parts by mass, preferably 0.01 to 0.02 parts by mass, of a surface active agent, preferably sodium lauryl sulfate, and if desired, 0.05 to 0.5 parts by mass, preferably 0.1 to 0.2 parts by mass of a lubricant, preferably magnesium stearate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU5621/88 | 1988-10-28 | ||
HU885621A HU200926B (en) | 1988-10-28 | 1988-10-28 | Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2001673A1 true CA2001673A1 (en) | 1990-04-28 |
CA2001673C CA2001673C (en) | 1996-08-27 |
Family
ID=10970484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002001673A Expired - Fee Related CA2001673C (en) | 1988-10-28 | 1989-10-27 | Pharmaceutical composition containing piroxicam |
Country Status (9)
Country | Link |
---|---|
JP (1) | JPH02172918A (en) |
AT (1) | AT399277B (en) |
CA (1) | CA2001673C (en) |
DE (1) | DE3936112C2 (en) |
FR (1) | FR2638357B1 (en) |
GB (1) | GB2224207B (en) |
HU (1) | HU200926B (en) |
IL (1) | IL92138A (en) |
IT (1) | IT1239542B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2642486B2 (en) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | Ultrafine particle method for poorly soluble drugs |
JP2964195B2 (en) * | 1992-04-28 | 1999-10-18 | エスエス製薬株式会社 | Piroxicam tablets and method for producing the same |
DE19603402A1 (en) * | 1995-02-24 | 1996-08-29 | Basf Ag | Soft gelatin capsules |
DK0914818T3 (en) * | 1996-06-14 | 2005-07-04 | Kyowa Hakko Kogyo Kk | Intraoral fast disintegrable tablet |
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
EP1070496A4 (en) * | 1998-04-08 | 2004-07-21 | Kyowa Hakko Kogyo Kk | Tablet manufacturing method and tablet |
JP2000095674A (en) | 1998-09-22 | 2000-04-04 | Sato Pharmaceutical Co Ltd | Production of tablet having shortened intraoral disintegration time and apparatus therefor |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
KR101072909B1 (en) * | 2002-12-16 | 2011-10-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | Solid drug for oral use |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
NZ709754A (en) | 2004-10-21 | 2017-02-24 | Adare Pharmaceuticals Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
ES2371414T3 (en) * | 2005-07-25 | 2012-01-02 | Otsuka Pharmaceutical Co., Ltd. | ORAL PREPARATION TO MEASURE THE METABOLIC CAPACITY OF PYRIMIDINE. |
KR101765357B1 (en) | 2009-12-02 | 2017-08-04 | 아데어 파마수티컬스 에스.알.엘. | Fexofenadine microcapsules and compositions containing them |
EP2887066B1 (en) | 2012-08-20 | 2020-08-05 | Otsuka Pharmaceutical Co., Ltd. | Composition for use in a method for measuring carbohydrate metabolism ability |
KR20150132301A (en) | 2013-03-15 | 2015-11-25 | 오츠카 세이야쿠 가부시키가이샤 | Method of measuring insulin resistance with fatty acid combustion, and composition used herein |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3591584A (en) * | 1968-08-27 | 1971-07-06 | Pfizer | Benzothiazine dioxides |
GB1308533A (en) * | 1969-06-02 | 1973-02-21 | Pfizer | Benzothiazine dioxides as anti-thombotic agents |
JPS55129221A (en) * | 1979-03-29 | 1980-10-06 | Kaken Pharmaceut Co Ltd | Preparation of oral preparation containing hardly soluble medicine |
US4350689A (en) * | 1980-02-15 | 1982-09-21 | American Cyanamid Company | Combinations of agents which give enhanced anti-inflammatory activity |
US4434164A (en) * | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Crystalline benzothiazine dioxide salts |
RO88420A (en) * | 1983-04-25 | 1986-01-30 | Pfizer Inc,Us | PROCEDURE FOR THE PREPARATION OF PIROXICAN BASIC BATCHES EMPTY ON PHARMACEUTICAL SUPPORTS |
DE3419128A1 (en) * | 1984-05-23 | 1985-11-28 | Bayer Ag, 5090 Leverkusen | DIHYDROPYRIDINE PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF |
CH663899A5 (en) * | 1985-03-20 | 1988-01-29 | Nestle Sa | PROCESS FOR THE PREPARATION OF A COMPOSITION BASED ON A FINELY DIVIDED LOW HYDROSOLUBILITY ACTIVE INGREDIENT. |
ES545221A0 (en) * | 1985-07-02 | 1986-01-01 | Ferrer Int | PROCEDURE FOR OBTAINING PARTICLES OF 4-HYDROXY-2-METHYL-N-2-PIRIDIL-2H-1,2-BENZOTIAZINE-3-CARBOXAMIDE-1,1-DIOXI-DO (PIROXICAM) COATED |
-
1988
- 1988-10-28 HU HU885621A patent/HU200926B/en unknown
-
1989
- 1989-10-19 JP JP1270514A patent/JPH02172918A/en active Pending
- 1989-10-27 CA CA002001673A patent/CA2001673C/en not_active Expired - Fee Related
- 1989-10-27 AT AT0247489A patent/AT399277B/en not_active IP Right Cessation
- 1989-10-27 FR FR8914117A patent/FR2638357B1/en not_active Expired - Fee Related
- 1989-10-27 IL IL9213889A patent/IL92138A/en not_active IP Right Cessation
- 1989-10-27 IT IT22164A patent/IT1239542B/en active IP Right Grant
- 1989-10-27 GB GB8924286A patent/GB2224207B/en not_active Expired - Lifetime
- 1989-10-30 DE DE3936112A patent/DE3936112C2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2001673C (en) | 1996-08-27 |
GB2224207A (en) | 1990-05-02 |
IL92138A (en) | 1994-08-26 |
DE3936112C2 (en) | 1999-02-18 |
GB8924286D0 (en) | 1989-12-13 |
IT8922164A0 (en) | 1989-10-27 |
IL92138A0 (en) | 1990-07-12 |
ATA247489A (en) | 1994-09-15 |
GB2224207B (en) | 1992-06-10 |
FR2638357A1 (en) | 1990-05-04 |
IT1239542B (en) | 1993-11-05 |
FR2638357B1 (en) | 1993-10-22 |
DE3936112A1 (en) | 1990-05-31 |
AT399277B (en) | 1995-04-25 |
HUT51143A (en) | 1990-04-28 |
HU200926B (en) | 1990-09-28 |
IT8922164A1 (en) | 1991-04-27 |
JPH02172918A (en) | 1990-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2001673A1 (en) | Pharmaceutical composition containing piroxicam | |
CA2232310A1 (en) | Stable compositions containing n-propargyl-1-aminoindan | |
HUT61324A (en) | Process for producing rhombic cyclosporin consisting of globular particles and new pulmonary pharmaceutical compositions comprising same as active ingredient | |
RU96118271A (en) | COMPOSITIONS CONTAINING FINE-CREATED NEBIVOL | |
ES2178943A1 (en) | Aerosol composition comprising formoterol | |
CA2229597A1 (en) | Oral fast-dissolving compositions for dopamine agonists | |
HUT61751A (en) | Process for producing benzofuran derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
GB2264640B (en) | Microcrystalline cellulose spheroids comprising hydromorphone and a sugar | |
CA2265766A1 (en) | Rapidly disintegrating pellets | |
CA2319308A1 (en) | Pharmaceutical agents | |
CA2059263A1 (en) | Composition comprising the (-) enantiomer of cis-4-amino-1-(2-hydromethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidine-2-one or an enriched composition thereof, and its uses as a pharmaceutical agent | |
PL299870A1 (en) | 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, crystalline hydrate of 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, method of obtaining these compounds, pharmaceutical preparation and method of fighting against bacteriae | |
MY122124A (en) | Solid pharmaceutical composition containing benzofurane derivatives | |
NO900370L (en) | NIFEDIPINE-CONTAINING PHARMACEUTICAL MIXTURES AND PROCEDURES FOR PREPARING THEREOF. | |
HUP0105463A2 (en) | Controlled release formulation of divalproex sodium | |
IL76332A0 (en) | Solid medicament formulation containing nitrendipine and its preparation | |
AU8188691A (en) | The use of inositoltrisphosphate for the preparing of medicaments | |
HUT52078A (en) | Herebicidal compositions comprising thiazole derivatives as active ingredient and process for producing the active ingredients | |
IE781032L (en) | Pharmaceutical compositions | |
WO2002056881A8 (en) | Fenofibrate tablets | |
CA2063273A1 (en) | Surfactant compositions and methods | |
IL99428A (en) | Pharmaceutical compositions containing ranitidine bismuth carboxylate salts | |
HUT59116A (en) | Process for producing oxazole derivatives and pharmaceutical compositions comprising oxazole derivatives as active ingredient | |
HU895241D0 (en) | Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient | |
GR3020828T3 (en) | Sustained release suppositories and a process for preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |